Catalog Advanced Search
-
Contains 1 Component(s)
This webinar will be important to Students, Trainees & Early-stage Professionals striving to develop relationships critical for career development and skills for self-awareness, leadership and problem solving. Attendees will learn how to develop and maintain successful mentoring relationships, build the network and resources to balance career with mental & emotional well-being, stay abreast of new developments and evolving technology and thrive in their careers.
2023 ACCP Student, Trainee & Early-stage Professional "Effectively Navigating the Mentee's Role in the Mentoring Journey" - On Demand
Live webinar: April 28, 2023 from 1:00 - 2:30 PM ET
On Demand webinar recording: May 31, 2023 to May 31, 2026Target Audience:
This webinar will be important to Students, Trainees & Early-stage Professionals striving to develop relationships critical for career development and skills for self-awareness, leadership and problem solving. Attendees will learn how to develop and maintain successful mentoring relationships, build the network and resources to balance career with mental & emotional well-being, stay abreast of new developments and evolving technology and thrive in their careers.
Learning Objective:
After completing this activity, the learner will be able to:
- Overcome fear, learn how to foster flexibility and effectively initiate mentorship-mentee relationships to meet needs that evolve over the various stages of career development;
- Identify deficiencies and create a holistic approach by understanding the scope of professional and personal colleagues required to support your professional journey;
- Fine tune skills for career planning and networking;
- Learn how to “pay it forward” to the next generation of clinical pharmacologists.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 4 Component(s), Includes Credits
This clinical webinar will introduce the Gut-Brain axis including a big-picture with relevant publications. The presentations will also discuss the link between the Gut-Brain, alcohol and addiction including examples of gut-brain-related neuroendocrine pathways (e.g., ghrelin, GLP-1) that may be relevant in alcohol addiction.
ACCP 2023 Clinical Practice Webinar - Leveraging Novel Microbiome-related Therapies-On Demand
On-demand webinar recording: May 24, 2023 to May 24, 2026
Why is this article important to your practice?
This clinical webinar will introduce the gut-brain axis including an overall perspective with relevant publications. The presentation will also discuss the link between the gut-brain, alcohol and other addiction (eating) disorders including examples of gut-brain-related neuroendocrine pathways (e.g., ghrelin, GLP-1) that may be relevant in the development of neuro-behavioral conditions such as addiction. Preliminary rat results will be presented from observations of binge-like alcohol drinking leading to changes in the gut microbiome in a manner independent from the presence or not (knock-out) of the ghrelin receptor. Additionally, results from a recently-published manuscript investigating the gut microbiome and metabolome of binge-drinking primates will be reviewed. Speakers will introduce an unpublished clinical protocol and will present preliminary gut microbiome data investigating the gut microbiome of abstinent and currently drinking individuals with alcohol use disorder (AUD) and controls.
Target Audience:
Physicians, Pharmacists, PhDs and healthcare professionals interested in clinical pharmacology.
Learning Objectives:
After completing this activity, the learner will be able to:
1. Identify the broad characterization of pathology associated with microbiome changes in several neurological conditions;
2. Estimate the correlations of microbial changes in neuro-behavioral statuses like eating disorders and AUD;
3. Assess why periodontitis is more common in AUD and compare the abundances of health- and periodontitis-associated previously identified genera to those in individuals with AUD;
4. Explore the influence of alcohol consumption and type of drinking and observe longitudinal-temporal changes in the oral microbiome in newly abstinent individuals undergoing inpatient treatment for AUD.
Lorenzo Leggio, MD, MPH
Clinical Director & Deputy Scientific Director, NIDA, Branch Chief
NIDA/NIAAA
Dr. Lorenzo Leggio is a Senior Investigator (Clinical) and Branch Chief in the NIH Intramural Research Program (IRP) with faculty appointments both at NIDA and NIAAA. He serves as Chief of the Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, a joint NIDA and NIAAA laboratory. He also serves as the NIDA Clinical Director and Deputy Scientific Director, plus other leadership roles within the NIH.. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and received Board Certification in Internal Medicine. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, he joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown Center for Alcohol and Addiction Studies, where he still holds an adjunct appointment as Professor in Behavioral and Social Sciences. He is also an Adjunct Professor of Addiction Medicine at Johns Hopkins University and of Neuroscience at Georgetown University. Dr. Leggio, together with his team, colleagues and collaborators have pioneered and conducted work on medication development, on the role of the microbiome-gut-liver-brain axis and on the role of neuroendocrine pathways in addictive behaviors via human laboratory studies and clinical trials as well as via translational and reverse translational experimental medicine approaches.
Lorenzo Leggio, MD, MPH, Clinical Director & Deputy Scientific Director, NIDA, Branch Chief, NIDA/NIAAA has no relevant financial relationship(s) with ineligible companies to disclose.
Jennifer J. Barb, PhD
Translational Bioinformatics Scientist
National Inst of Health
Dr. Jennifer Barb has been a bioinformatics scientist at the NIH for over 20 years and is currently the unit head of the Data Analytics and Translational Science in the Translational Biobehavioral and Health Disparities Branch at the NIH Clinical Center. Dr. Barb has a wide range of experience in investigating human clinical data and high-throughput gene expression analysis. She has been studying the oral and gut microbiome of individuals with Alcohol Use Disorder and also the role of nutrition and sleep on the addiction for over 8 years. Throughout her career at the NIH, she has collaborated with many intramural institutes including the Forsyth Institute and the Framingham Heart Study. She has coauthored over 50 peer-reviewed publications.
Jennifer J. Barb, PhD, Translational Bioinformatics Scientist, National Inst of Health has no relevant financial relationship(s) with ineligible companies to disclose.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 5 Component(s), Includes Credits
For rare diseases, it is challenging to enroll a large number of patients and obtain all critical information to support drug approval through traditional clinical trial approaches. In addition, over half of the population affected by rare diseases are children, which presents additional drug development challenges. In the context of rare diseases, maximizing the use of all available data is in the interest of drug developers and regulators. This provides opportunities for model-informed drug development(MIDD) to use and integrate all available sources and knowledge to quantitatively assess the benefit/risk of a new product under development and to inform dosing. Learners that complete this activity will be able to explain the application of MIDD in rare diseases.
2023 ACCP Virtual Journal Club Webinar: Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases - On Demand
On-demand webinar recording: May 17th, 2023 to May 17th, 2026
Why is this article important to your practice?
For rare diseases, it is challenging to enroll a large number of patients and obtain all critical information to support drug approval through traditional clinical trial approaches. In addition, over half of the population affected by rare diseases are children, which presents additional drug development challenges. In the context of rare diseases, maximizing the use of all available data is in the interest of drug developers and regulators. This provides opportunities for model-informed drug development(MIDD) to use and integrate all available sources and knowledge to quantitatively assess the benefit/risk of a new product under development and to inform dosing. Learners that complete this activity will be able to explain the application of MIDD in rare diseases.
Target Audience:
Physicians, Pharmacists, PhDs and other healthcare professionals interested in the application of model-informed drug development.
Learning Objectives
After completing this activity, the learner will be able to:
- Explain why MIDD is important for rare diseases;
- Discuss how MIDD can be applied to enhance drug development for rare diseases;
- Learn about the future direction for MIDD application to enhance drug development for rare diseases.
Hao Zhu, PhD
Team Leader
U.S. Food & Drug Administration
Dr. Hao Zhu is the Director of the Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Science, Center of Drug Evaluation and Research, U.S. Food and Drug Administration. Dr. Zhu received his Ph.D. in pharmaceutical sciences and Master in statistics from the University of Florida. He started his career in modeling and simulation teams in Johnson & Johnson and Bristol-Myers-Squibb. He joined FDA as a pharmacometrics reviewer more than 16 years ago. Dr. Zhu has been a clinical pharmacology team leader for more than 6 years and a QT-IRT scientific lead for 2 years. Then he became the deputy director at the Division of Pharmacometrics. His division reviews the pharmacometrics related submissions and supports pharmacometrics-related policy development.
Hao Zhu, PhD, Team Leader, US Food & Drug Administration, Faculty, has no relevant financial relationship(s) with ineligible companies to disclose.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 9 Product(s)
The program includes a series of 10-15 pre-recorded courses, translates foundational clinical pharmacology content from these articles into short vignette-based teaching scenarios that appeal to the preferred learning style of current medical and pharmacy students.
Clinical Pharmacology Education: Pearls for Practice®
Why is this Program important to you?
The Clinical Pharmacology Education: Pearls for Practice® Program is based on the Core Entrustable Professional Activities (EPA) identified by The Association of American Medical Colleges Council of Faculty and Academic Societies for medical students and the American Association of Colleges of Pharmacy (AACP) for pharmacy students. ACCP developed a set of standards representing the Core EPA in clinical pharmacology based on a series of published articles in The Journal of Clinical Pharmacology. The program, which includes a series of 10-15 pre-recorded courses, translates foundational clinical pharmacology content from these articles into short vignette-based teaching scenarios that appeal to the preferred learning style of current medical and pharmacy students. They are also written at a level that challenges the advance 4th year medical/pharmacy students.
ACCP’s Pearls for Practice Program is a mechanism to reintroduce didactic clinical pharmacology education into the schools of pharmacy and medicine which have reduced some of these basic sciences in favor of early clinical rotations.
Target Audience:
4th year medical/pharmacy students. In addition, students of graduate and professional doctorate programs.
Instructions: In order to earn the Pearls for Practice® Electronic Badge, please complete up to 5 of the 8 courses available.
-
You must log in to register
- Member - $120
- More Information
-
You must log in to register
-
Contains 24 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact atruluck@accp1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated into their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits automatically uploaded to the CPE Monitor.
CE Expiration 12/31/2026
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 3 Component(s)
Drug-induced nephrotoxicity (DIN) is a major clinical challenge for a variety of marketed drugs belonging to various therapeutic areas. Successful clinical prevention of DIN requires prior knowledge of drug’s mechanism of action coupled with pathogenic mechanisms of renal injury as well as patient- and drug-related risk factors. Recently, significant innovative advances in the identification of novel early biomarkers for DIN have been made. However, they are not beyond limitations. In such scenarios, mathematical modeling and simulation (M&S) may be used as a robust tool to understand and predict DIN in a clinical setting. This presentation highlights some of the recent advancements in mathematical M&S approaches for DIN. An example of the utility of multiscale and translational M&S for combinatorial effects of a DIN with a proposed preventive therapeutic will be showcased.
2023 ACCP Virtual Journal Club Webinar: A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches - On-Demand
Live webinar: February 16, 2023 from 2:00 - 3:00 PM ET
On-demand webinar recording: February 16, 2023 to February 16, 2026
Why is this article important to your practice?
Drug-induced nephrotoxicity (DIN) is a major clinical challenge for a variety of marketed drugs belonging to various therapeutic areas. Successful clinical prevention of DIN requires prior knowledge of drug’s mechanism of action coupled with pathogenic mechanisms of renal injury as well as patient- and drug-related risk factors. Recently, significant innovative advances in the identification of novel early biomarkers for DIN have been made. However, they are not beyond limitations. In such scenarios, mathematical modeling and simulation (M&S) may be used as a robust tool to understand and predict DIN in a clinical setting. This presentation highlights some of the recent advancements in mathematical M&S approaches for DIN. An example of the utility of multiscale and translational M&S for combinatorial effects of a DIN with a proposed preventive therapeutic will be showcased.
Target Audience:
Physicians, Pharmacists, PhDs.
Learning Objectives
After completing this activity, the learner will be able to:
1) Review the various mechanisms of DIN and highlight the associated classes of nephrotoxic drugs;
2) Describe the current approach to prevention, diagnosis and management of drug-induced nephrotoxicity;
3) Summarize recent advances in the role of mathematical M&S in DIN.
Sihem Bihorel, PharmD, PhD
Principal Scientist-Scientific Director
Merck & Co Inc
Dr. Sihem Bihorel is currently a Principal Scientist (Scientific Director) at Merck & Co. Prior to joining Merck, she was an Assistant Professor at the College of Pharmacy at the University of Florida. Dr. Bihorel holds a Master's degrees in Immunology and in Pharmacometrics, a PharmD, and a PhD. Following her PhD research conducted in the Department of Pharmaceutical Sciences at SUNY at Buffalo, she pursued a Postdoctoral Associate position, followed by a Research Assistant Professor position in the same department. Her expertise is in the end-to-end application of model-informed drug development with a variety of quantitative approaches and in various therapeutic areas. Sihem has authored numerous scientific publications in international peer-reviewed journals, book chapters, and presented her work as posters, talks, and webinars at various international conferences. She is also a mentor to many students, postdocs, scholars, and scientists in academia, the pharmaceutical industry, and the International Society of Pharmacometrics.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 48 Component(s), Includes Credits
The American College of Clinical Pharmacology® monthly journal article continuing education offerings from The Journal of Clinical Pharmacology.
Registration and Pricing
The American College of Clinical Pharmacology® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.
To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact KLevy@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.
Requirements for Credits
All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated into their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits automatically uploaded to the CPE Monitor.
CE Expiration 12/31/2025
-
You must log in to register
- User - $75
- Member - Free!
- More Information
-
You must log in to register
-
Contains 2 Component(s)
The networking event is uniquely designed to address the career development needs of Early-stage Professionals (ESPs) particularly, provide guidance, mentoring and development of translatable skills while navigating career transition from an individual contributor level to being a first-time manager within an organization. ESPs are highly encouraged to participate in the panel discussion with several distinguished ACCP senior colleagues and learn from their professional journey.
2022 ACCP Early-stage Professionals Mid-Year Networking: Strategies and Skills For New and Future Managers - On Demand
Why is this webinar important to you?
The networking event is uniquely designed to address the career development needs of Early-stage Professionals (ESPs) particularly, provide guidance, mentoring and development of translatable skills while navigating career transition from an individual contributor level to being a first-time manager within an organization. ESPs are highly encouraged to participate in the panel discussion with several distinguished ACCP senior colleagues and learn from their professional journey.
Target Audience:
Students, Trainees & Early-stage Professionals (1 - 10 years in first full-time position).
Learning Objective:
After completing this activity, the learner will be able to:
- Early-stage Professionals will learn how to navigate the transition from being an individual contributor level to a first-time manager;
- Learn how to effectively interact with one’s line management;
- Learn how to identify existing gaps in professional development related to people management and how honing one's leadership skills can help others to achieve their potential;
- Learn how to develop the key translatable skills in successfully managing in a variety of circumstances, including teams, peers and direct reports.
Faculty Speakers
- Dr. Angela James, Vice President, Head of Clinical Pharmacology, MacroGenics Inc
- Dr. Stacey Tannenbaum, Executive Director, Pharmacometrics US, Astellas Pharma
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
Contains 5 Component(s), Includes Credits
Presented by: Catherijne AJ Knibbe, PhD, PharmD
Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children-On Demand
ACCP Virtual Journal Club Webinars
Live Webinar: August 10, 2022, 2:00 - 3:00 PM ET
On Demand: August 10, 2022 to August 10, 2025
See Handouts tab for Continuing Education information on CME and CPE credits.
Why is this webinar important to you?
There is only limited study into the pharmacodynamics of morphine for postoperative use in children, while the pharmacokinetics of morphine has been studied extensively. The effects of morphine in children after surgery are generally registered using behavior pain scales like the COMFORT-Behavior (COMFORT-B) scale. This scale consists of six behavioral items that quantify pain-associated behavior and symptoms as a proxy for the level of pain, each ranging from 1 (low distress/pain) to 5 (high distress/pain). As such, the total COMFORT-B score ranges from 6 to 30, for which scores of 11 to 16 are clinically aimed for during titration. To quantify the concentration-effect relationship of morphine for postoperative pain in preverbal children between 0 and 3 years of age, we applied Item Response Theory modeling in the pharmacokinetic/pharmacodynamic analysis of COMFORT-B scale data from two previous pediatric clinical studies. Learners that complete this course, will be able to explain the pharmacodynamics of morphine across the pediatric age range.
Target Audience
Physicians, Pharmacists, PhDs and Physician Assistants.Learning Objectives
After completing this activity, the learner will be able to:1) Define the target concentration of morphine throughout childhood;
2) Identify non-responders to morphine up-titration.
To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.
Catherijne Knibbe, PhD, PharmD
Professor
St Antonius Hosp/Leiden Univ
Catherijne Knibbe, PharmD, PhD is Professor of Individualized Drug Treatment at the Division of Systems Pharmacology and Pharmacy of the LACDR, Leiden University, and clinical pharmacologist-hospital pharmacist at the Department of Clinical Pharmacy of the St. Antonius Hospital, Nieuwegein, the Netherlands. She also holds a guest appointment at the Erasmus MC, Sophia Childrens Hospital Rotterdam.
Dr. Knibbe’s primary research focus is to optimize individualized drug treatment for special patient populations such as neonates and children, the elderly and morbidly obese pediatric and adult patients. To this end, she applies advanced statistical and pharmacometric approaches such as population PKPD modelling and PBPK modelling, to existing or newly derived data. To obtain these data, she has designed and conducted a large number of clinical studies not only within her own institution but also with many collaborating hospitals in Europe and the US, supported by different grant mechanisms. She has successfully supervised 23 PhD students, and currently is supervising 10 PhD students and 3 Post Docs/Assistant Professors. She is a co-author of over 250 international peer-reviewed publications and contributions to books. Catherijne is frequently invited to speak at national and international scientific meetings. In the St. Antonius Hospital, besides being member of the Daily Board, she directs the Clinical Pharmacology training program and the Hospital Pharmacy training program. In addition she is a clinical pharmacology consultant for the departments of Intensive Care and Anesthesiology. She serves on different national and international committees including the Board of the American College of Clinical Pharmacology.
Nothing to disclose.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register
-
Contains 10 Component(s)
The ACCP Fundamentals Tutorials series is designed to provide a "not too technical" overview of clinical pharmacology and is ideal for Students & Trainees or those looking to supplement information not available in your curriculum. Each course is offered as a Live webinar featuring a presentation followed by questions and discussion. The registration fee is $40/Members, $50/Non-members, $20/Student Members and $25/Student Non-member.
ACCP Fundamentals Tutorials Certificate Program
On-demand webinar recording: June 22, 2022 to June 22, 2025
Why is this article important to your practice?
The ACCP Fundamentals Tutorials series is designed to provide a "not too technical" overview of clinical pharmacology and is ideal for Students & Trainees or those looking to supplement information not available in your curriculum.
Target Audience:
Professionals in academic, pharmaceutical/private sector and regulatory settings involved in drug disposition, clinical pharmacology and pharmacometrics. In addition, Students of graduate and professional doctorate programs.
-
You must log in to register
- User - Free!
- Member - Free!
- More Information
-
You must log in to register